Praxis Precision Medicines (PRAX) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Tango Therapeutics (TNGX) over the past year, gaining 434.2% versus a gain of 226.6%. Over five years, TNGX leads with a +60.9% price change compared with -7.4% for PRAX. Praxis Precision Medicines is the larger company by market cap ($7.36 billion vs $3.81 billion), about 1.9 times the size, while Tango Therapeutics is growing revenue faster (+48.3% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | TNGX |
|---|---|---|
| Share price | $263.55 | $22.57 |
| Market cap | $7.36B | $3.81B |
| 1-day change | -5.20% | +3.39% |
| YTD return | -5.67% | +154.74% |
| 1-year return | +434.24% | +226.63% |
| 5-year return | -7.37% | +60.87% |
| EPS (TTM) | $-12.95 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $62.38M |
| Revenue growth (YoY) | -100.00% | +48.29% |
| Net income (latest FY) | $-303.27M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $392.70 | $34.39 |
| 52-week low | $50.56 | $6.69 |
| Distance from 52-week high | -32.89% | -34.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +144.52% | +100.18% |
| Average volume | 403.18K | 2.61M |
| Shares outstanding | 27.92M | 168.61M |
| Employees | 168 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed TNGX by 207.6 percentage points over the past year.
- Tango Therapeutics grew revenue faster in its latest fiscal year (+48.29% vs -100.00%).
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
PRAX vs TNGX FAQ
Which is bigger, Praxis Precision Medicines or Tango Therapeutics?
Praxis Precision Medicines (PRAX) is larger, with a market capitalization of $7.36B compared with $3.81B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, PRAX or TNGX?
PRAX returned +434.24% over the past 12 months, compared with +226.63% for TNGX (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.